Ketamine and Spravato are related but not identical treatments.

Spravato is the brand name for esketamine, a specific component of ketamine that has been FDA-approved for treatment-resistant depression and is administered through a structured REMS (Risk Evaluation and Mitigation Strategy) program.

Ketamine is often provided through infusion clinics and may be used off-label for mental health conditions, and is therefore not covered by insurance.

While both treatments affect glutamate pathways in the brain and may be beneficial for depression, they differ in formulation, administration, monitoring requirements, and FDA approval status.